Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Manchester United PLC — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Manchester United PLC trades at $22.2 (market cap $3.80B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 10.5× Manchester United PLC's market cap, and Manchester United PLC pays a 1.26% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MANU | |
|---|---|---|
Market Cap | $39.89B | $3.80B |
Sector | Health | Media |
52-Week High | $491.22 | $23.53 |
52-Week Low | $278.09 | $15.10 |
Enterprise Value | $38.15B | $4.72B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Manchester United (MANU) trades at $22.04, up 0.18% today, with a bullish technical signal and positive news flow around stadium development. The company reported mixed quarterly earnings but achieved Champions League qualification, boosting future revenue prospects. However, fundamentals show persistent net losses and negative ROE, with a high P/B ratio of 16.05 indicating premium valuation despite profitability challenges.
The outlook is cautiously optimistic, driven by stadium expansion plans and improved sporting performance, but significant execution risks and ongoing financial losses warrant careful monitoring. Analyst sentiment is mixed with 40% buy ratings, reflecting the balance between growth potential and current weak profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
